Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel

Jiyoung Park; Yonghwan Choi; Junghyun Namkung; Sung Gon Yi; Hyunsoo Kim; Jiyoung Yu; Yongkang Kim; Min Seok Kwon; Wooil Kwon; Do Youn Oh; Sun Whe Kim; Seung Yong Jeong; Wonshik Han; Kyu Eun Lee; Jin Seok Heo; Joon Oh Park; Joo Kyung Park; Song Cheol Kim; Chang Moo Kang; Woo Jin Lee; Seungyeoun Lee; Sangjo Han; Taesung Park; Jin Young Jang; Youngsoo Kim

doi:10.18632/oncotarget.21861

Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel

Jiyoung Park, Yonghwan Choi, Junghyun Namkung, Sung Gon Yi, Hyunsoo Kim, Jiyoung Yu, Yongkang Kim, Min Seok Kwon, Wooil Kwon, Do Youn Oh, Sun Whe Kim, Seung Yong Jeong, Wonshik Han, Kyu Eun Lee, Jin Seok Heo, Joon Oh Park, Joo Kyung Park, Song Cheol Kim, Chang Moo Kang, Woo Jin LeeSeungyeoun Lee, Sangjo Han, Taesung Park, Jin Young Jang, Youngsoo Kim

Department of Surgery

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Due to its high mortality rate and asymptomatic nature, early detection rates of pancreatic ductal adenocarcinoma (PDAC) remain poor. We measured 1000 biomarker candidates in 134 clinical plasma samples by multiple reaction monitoring-mass spectrometry (MRM-MS). Differentially abundant proteins were assembled into a multimarker panel from a training set (n=684) and validated in independent set (n=318) from five centers. The level of panel proteins was also confirmed by immunoassays. The panel including leucine-rich alpha-2 glycoprotein (LRG1), transthyretin (TTR), and CA19-9 had a sensitivity of 82.5% and a specificity of 92.1%. The triple-marker panel exceeded the diagnostic performance of CA19-9 by more than 10% (AUC_CA19-9 = 0.826, AUC_panel= 0.931, P < 0.01) in all PDAC samples and by more than 30% (AUC_CA19-9 = 0.520, AUC_panel = 0.830, P < 0.001) in patients with normal range of CA19-9 ( < 37U/mL). Further, it differentiated PDAC from benign pancreatic disease (AUC_CA19-9 = 0.812, AUC_panel = 0.892, P < 0.01) and other cancers (AUC_CA19-9 = 0.796, AUC_panel = 0.899, P < 0.001). Overall, the multimarker panel that we have developed and validated in largescale samples by MRM-MS and immunoassay has clinical applicability in the early detection of PDAC.

Original language	English
Pages (from-to)	93117-93130
Number of pages	14
Journal	Oncotarget
Volume	8
Issue number	54
DOIs	https://doi.org/10.18632/oncotarget.21861
Publication status	Published - 2017

Bibliographical note

Funding Information:
This work was supported by the Collaborative Genome Program for Fostering New Post-Genome Industry(NRF-2017M3C9A5031597), a National Research Foundation grant (No. 2011-0030740), the Industrial Strategic Technology Development Program (#10079271), a grant from the Korea Health Technology R&D Project (No. HI16C2037, HI14C2640), and the SK Telecom Research Fund.

Publisher Copyright:
© Park et al.

All Science Journal Classification (ASJC) codes

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.18632/oncotarget.21861

Cite this

Park, J., Choi, Y., Namkung, J., Yi, S. G., Kim, H., Yu, J., Kim, Y., Kwon, M. S., Kwon, W., Oh, D. Y., Kim, S. W., Jeong, S. Y., Han, W., Lee, K. E., Heo, J. S., Park, J. O., Park, J. K., Kim, S. C., Kang, C. M., ... Kim, Y. (2017). Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Oncotarget, 8(54), 93117-93130. https://doi.org/10.18632/oncotarget.21861

@article{08e079b64a804763a6e5d0691301c0b0,

title = "Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel",

abstract = "Due to its high mortality rate and asymptomatic nature, early detection rates of pancreatic ductal adenocarcinoma (PDAC) remain poor. We measured 1000 biomarker candidates in 134 clinical plasma samples by multiple reaction monitoring-mass spectrometry (MRM-MS). Differentially abundant proteins were assembled into a multimarker panel from a training set (n=684) and validated in independent set (n=318) from five centers. The level of panel proteins was also confirmed by immunoassays. The panel including leucine-rich alpha-2 glycoprotein (LRG1), transthyretin (TTR), and CA19-9 had a sensitivity of 82.5% and a specificity of 92.1%. The triple-marker panel exceeded the diagnostic performance of CA19-9 by more than 10% (AUCCA19-9 = 0.826, AUCpanel= 0.931, P < 0.01) in all PDAC samples and by more than 30% (AUCCA19-9 = 0.520, AUCpanel = 0.830, P < 0.001) in patients with normal range of CA19-9 ( < 37U/mL). Further, it differentiated PDAC from benign pancreatic disease (AUCCA19-9 = 0.812, AUCpanel = 0.892, P < 0.01) and other cancers (AUCCA19-9 = 0.796, AUCpanel = 0.899, P < 0.001). Overall, the multimarker panel that we have developed and validated in largescale samples by MRM-MS and immunoassay has clinical applicability in the early detection of PDAC.",

author = "Jiyoung Park and Yonghwan Choi and Junghyun Namkung and Yi, {Sung Gon} and Hyunsoo Kim and Jiyoung Yu and Yongkang Kim and Kwon, {Min Seok} and Wooil Kwon and Oh, {Do Youn} and Kim, {Sun Whe} and Jeong, {Seung Yong} and Wonshik Han and Lee, {Kyu Eun} and Heo, {Jin Seok} and Park, {Joon Oh} and Park, {Joo Kyung} and Kim, {Song Cheol} and Kang, {Chang Moo} and Lee, {Woo Jin} and Seungyeoun Lee and Sangjo Han and Taesung Park and Jang, {Jin Young} and Youngsoo Kim",

note = "Funding Information: This work was supported by the Collaborative Genome Program for Fostering New Post-Genome Industry(NRF-2017M3C9A5031597), a National Research Foundation grant (No. 2011-0030740), the Industrial Strategic Technology Development Program (#10079271), a grant from the Korea Health Technology R&D Project (No. HI16C2037, HI14C2640), and the SK Telecom Research Fund. Publisher Copyright: {\textcopyright} Park et al.",

year = "2017",

doi = "10.18632/oncotarget.21861",

language = "English",

volume = "8",

pages = "93117--93130",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "54",

}

Park, J, Choi, Y, Namkung, J, Yi, SG, Kim, H, Yu, J, Kim, Y, Kwon, MS, Kwon, W, Oh, DY, Kim, SW, Jeong, SY, Han, W, Lee, KE, Heo, JS, Park, JO, Park, JK, Kim, SC, Kang, CM, Lee, WJ, Lee, S, Han, S, Park, T, Jang, JY & Kim, Y 2017, 'Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel', Oncotarget, vol. 8, no. 54, pp. 93117-93130. https://doi.org/10.18632/oncotarget.21861

TY - JOUR

T1 - Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel

AU - Park, Jiyoung

AU - Choi, Yonghwan

AU - Namkung, Junghyun

AU - Yi, Sung Gon

AU - Kim, Hyunsoo

AU - Yu, Jiyoung

AU - Kim, Yongkang

AU - Kwon, Min Seok

AU - Kwon, Wooil

AU - Oh, Do Youn

AU - Kim, Sun Whe

AU - Jeong, Seung Yong

AU - Han, Wonshik

AU - Lee, Kyu Eun

AU - Heo, Jin Seok

AU - Park, Joon Oh

AU - Park, Joo Kyung

AU - Kim, Song Cheol

AU - Kang, Chang Moo

AU - Lee, Woo Jin

AU - Lee, Seungyeoun

AU - Han, Sangjo

AU - Park, Taesung

AU - Jang, Jin Young

AU - Kim, Youngsoo

N1 - Funding Information: This work was supported by the Collaborative Genome Program for Fostering New Post-Genome Industry(NRF-2017M3C9A5031597), a National Research Foundation grant (No. 2011-0030740), the Industrial Strategic Technology Development Program (#10079271), a grant from the Korea Health Technology R&D Project (No. HI16C2037, HI14C2640), and the SK Telecom Research Fund. Publisher Copyright: © Park et al.

PY - 2017

Y1 - 2017

N2 - Due to its high mortality rate and asymptomatic nature, early detection rates of pancreatic ductal adenocarcinoma (PDAC) remain poor. We measured 1000 biomarker candidates in 134 clinical plasma samples by multiple reaction monitoring-mass spectrometry (MRM-MS). Differentially abundant proteins were assembled into a multimarker panel from a training set (n=684) and validated in independent set (n=318) from five centers. The level of panel proteins was also confirmed by immunoassays. The panel including leucine-rich alpha-2 glycoprotein (LRG1), transthyretin (TTR), and CA19-9 had a sensitivity of 82.5% and a specificity of 92.1%. The triple-marker panel exceeded the diagnostic performance of CA19-9 by more than 10% (AUCCA19-9 = 0.826, AUCpanel= 0.931, P < 0.01) in all PDAC samples and by more than 30% (AUCCA19-9 = 0.520, AUCpanel = 0.830, P < 0.001) in patients with normal range of CA19-9 ( < 37U/mL). Further, it differentiated PDAC from benign pancreatic disease (AUCCA19-9 = 0.812, AUCpanel = 0.892, P < 0.01) and other cancers (AUCCA19-9 = 0.796, AUCpanel = 0.899, P < 0.001). Overall, the multimarker panel that we have developed and validated in largescale samples by MRM-MS and immunoassay has clinical applicability in the early detection of PDAC.

AB - Due to its high mortality rate and asymptomatic nature, early detection rates of pancreatic ductal adenocarcinoma (PDAC) remain poor. We measured 1000 biomarker candidates in 134 clinical plasma samples by multiple reaction monitoring-mass spectrometry (MRM-MS). Differentially abundant proteins were assembled into a multimarker panel from a training set (n=684) and validated in independent set (n=318) from five centers. The level of panel proteins was also confirmed by immunoassays. The panel including leucine-rich alpha-2 glycoprotein (LRG1), transthyretin (TTR), and CA19-9 had a sensitivity of 82.5% and a specificity of 92.1%. The triple-marker panel exceeded the diagnostic performance of CA19-9 by more than 10% (AUCCA19-9 = 0.826, AUCpanel= 0.931, P < 0.01) in all PDAC samples and by more than 30% (AUCCA19-9 = 0.520, AUCpanel = 0.830, P < 0.001) in patients with normal range of CA19-9 ( < 37U/mL). Further, it differentiated PDAC from benign pancreatic disease (AUCCA19-9 = 0.812, AUCpanel = 0.892, P < 0.01) and other cancers (AUCCA19-9 = 0.796, AUCpanel = 0.899, P < 0.001). Overall, the multimarker panel that we have developed and validated in largescale samples by MRM-MS and immunoassay has clinical applicability in the early detection of PDAC.

UR - http://www.scopus.com/inward/record.url?scp=85032674237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032674237&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21861

DO - 10.18632/oncotarget.21861

M3 - Article

C2 - 29190982

AN - SCOPUS:85032674237

SN - 1949-2553

VL - 8

SP - 93117

EP - 93130

JO - Oncotarget

JF - Oncotarget

IS - 54

ER -

Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this